Caristo Diagnostics Launches Pioneering CaRi-Heart® Technology in NHS Hospitals to Enhance CAD Management
Caristo Diagnostics Limited, a pioneer in the field of cardiac and vascular disease diagnostics and risk prediction, is thrilled to announce the deployment of its groundbreaking CaRi-Heart® technology across select National Health Service (NHS) hospitals. This initiative, supported by NHS England, aims to revolutionize coronary artery disease (CAD) management through a pilot pathway program involving five distinguished NHS trusts.
The pilot, incorporating University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospital NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust, will offer patients undergoing CCTA scans at Rapid Access Chest Pain Clinics (RACPCs) an advanced analysis through the CaRi-Heart platform. This innovative approach is designed to enhance cardiac risk assessment and refine medical management strategies for those at risk.
The CaRi-Heart platform, recently launched in the UK and EU markets, is a testament to the latest advancements in AI-driven cardiac care. It uniquely identifies coronary inflammation and atherosclerotic plaque from standard cardiac CT scans, offering a comprehensive view of a patient’s cardiac health. The addition of the CaRi-PlaqueTM module to the platform allows for detailed analysis of coronary plaque characteristics, aiding clinicians in pinpointing patients who would benefit most from mechanical thrombectomy (MT) – a procedure that significantly reduces disability and long-term care needs in severe stroke cases.
The implementation of CaRi-Heart technology signifies a major step forward in CAD management, enabling rapid identification and optimal treatment planning for patients with critical cardiac conditions. Interim results from an independent evaluation conducted by the Oxford AHSN have shown a remarkable increase in treatment rates at e-Stroke hospitals, underscoring the platform’s potential to transform patient outcomes.
Caristo Diagnostics CEO, Frank Cheng, expressed enthusiasm about the collaboration with NHS England and the anticipated impact of CaRi-Heart technology on global cardiac care standards. Caristo’s mission to advance disease diagnostics and risk prediction is further exemplified by the CaRi-Heart technology’s accolades and the support it has garnered from the medical community and investors alike.
The CaRi-Heart technology, distinguished for its innovative approach to coronary inflammation and plaque analysis, is poised to redefine cardiac healthcare. With its robust clinical validation and readiness for implementation, Caristo Diagnostics and its NHS partners are set to offer patients a new lease on life, emphasizing the importance of early intervention and precise risk assessment in preventing heart attacks.
For more information about Caristo Diagnostics and the CaRi-Heart technology, visit the Caristo website and follow the company on LinkedIn and Twitter.
